PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 2, 2026ESMO Open2 citationsOpen Access

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

View Full Paper
EAE.S.M. van AkenSOS.M. O’CathailAGA.K. Gandhi

Key Points

  • The aim is to assess the safety of combining radiotherapy with specific targeted agents including EGFR, ALK, and BRAF/MEK inhibitors.
  • Consensus statements developed by ESMO and ESTRO experts
  • Evaluation of scenarios for drug interruptions or dosage reductions
  • Assessment of radiotherapy adaptation strategies.
  • Increased toxicity is likely when combining treatments
  • Recommendations for drug interruption or reduction to manage risks
  • Advocacy for significant adjustments in radiotherapy protocols.

Abstract

For most scenarios, concurrently combining RT with targeted agents may lead to increased toxicity. Therefore, we recommend a drug interruption, a drug dosage reduction, or a major RT adaptation in various scenarios.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Aken et al. (2026) studied this question.

synapsesocial.com/papers/69a528b3f1e85e5c73bf031ehttps://doi.org/10.1016/j.esmoop.2026.106076
Ask AI
Helpful
Bookmark
Share
View Full Paper